» Articles » PMID: 32714986

Potential of Using Cell-Free DNA and MiRNA in Breast Milk to Screen Early Breast Cancer

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2020 Jul 28
PMID 32714986
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: An ideal sample source is critical for more reliable and sensitive early detection of nucleic acid changes associated with breast cancer. Breast milk (BM) is a good noninvasive origin for genetic testing of early breast cancer, but cells in BM are easily disintegrated. So we investigate here whether cell-free nucleic acid (cfNA) exists in BM in a more stable form and whether the quality of BM cfNA is good enough for genetic testing.

Methods: A self-designed qRT-PCR method was used to measure the existence and abundance of cfDNA. Quality of cfDNA and cfRNA were detected by capillary electrophoresis. Whole genome bisulfite sequencing and miRNA sequencing were used to explore the sources of cfDNA and cell-free miRNA in BM. The copy number analysis and -test based on whole genome sequencing data were used to determine the integrity of genetic information in BM cfNA.

Results: We found that cell-free DNA and miRNA exist in the studied breast milk samples in a stable form that can tolerate incubation of BM at room temperature for at least 7 days. These cell-free nucleic acids come mainly from breast-derived cells and contain genetic information as good integrity as in BM cells. We further listed some candidate miRNAs as potential biomarkers for research of early breast cancer screening by analysis of previous reports and our data.

Conclusions: Our results suggest that cfDNA and cell-free miRNA in BM might be new noninvasive sample sources for finding early alterations of nucleic acid associated with the initiation and progression of breast cancer.

Citing Articles

The Role of Breast Milk Cell-Free DNA in the Regulation of the Neonatal Immune Response.

Rezai T, Fell-Hakai S, Guleria S, Toldi G Nutrients. 2025; 16(24.

PMID: 39770994 PMC: 11678730. DOI: 10.3390/nu16244373.


Investigation of Plasma Cell-Free DNA and MiRNA in Cholangiocarcinoma and Opisthorchiasis Viverrini Patients.

Prasopdee S, Pholhelm M, Yusuk S, Tangphatsornruang S, Butthongkomvong K, Kunjantarachot A Asian Pac J Cancer Prev. 2024; 25(3):739-746.

PMID: 38546056 PMC: 11152403. DOI: 10.31557/APJCP.2024.25.3.739.


Deciphering a proteomic signature for the early detection of breast cancer from breast milk: the role of quantitative proteomics.

Whitham D, Bruno P, Haaker N, Arcaro K, Pentecost B, Darie C Expert Rev Proteomics. 2024; 21(1-3):81-98.

PMID: 38376826 PMC: 11694492. DOI: 10.1080/14789450.2024.2320158.


Potential utility of miRNAs for liquid biopsy in breast cancer.

Liu X, Papukashvili D, Wang Z, Liu Y, Chen X, Li J Front Oncol. 2022; 12:940314.

PMID: 35992785 PMC: 9386533. DOI: 10.3389/fonc.2022.940314.


Evaluation of cfDNA as an early detection assay for dense tissue breast cancer.

Barbirou M, Miller A, Gafni E, Mezlini A, Zidi A, Boley N Sci Rep. 2022; 12(1):8458.

PMID: 35589867 PMC: 9120463. DOI: 10.1038/s41598-022-12457-1.


References
1.
Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

2.
El-Hefnawy T, Raja S, Kelly L, Bigbee W, Kirkwood J, Luketich J . Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004; 50(3):564-73. DOI: 10.1373/clinchem.2003.028506. View

3.
Fleischhacker M, Schmidt B . Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2006; 1775(1):181-232. DOI: 10.1016/j.bbcan.2006.10.001. View

4.
Cohen J, Li L, Wang Y, Thoburn C, Afsari B, Danilova L . Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018; 359(6378):926-930. PMC: 6080308. DOI: 10.1126/science.aar3247. View

5.
Diaz Jr L, Bardelli A . Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32(6):579-86. PMC: 4820760. DOI: 10.1200/JCO.2012.45.2011. View